We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ACEi and ARB with COVID-19.
- Authors
Khashkhusha, Taqua R.; Chan, Jeffrey Shi Kai; Harky, Amer
- Abstract
We thank the author for their comments on our article "ACE inhibitors and COVID-19: We don't know yet" regarding the controversies for the use of angiotensin-converting enzymes (ACE) inhibitors (ACEi) in novel coronavirus disease-19 (COVID-19) and whether it is beneficial or harmful. A review article[4] suggested the replacement of the renin-angiotensin-aldosterone system (RAAS) associated antihypertensives with drugs which are neutral concerning angiotensin II availability such as calcium channel blockers. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.
- Subjects
COVID-19; ANGIOTENSIN-receptor blockers; ALDOSTERONE antagonists; COVID-19 pandemic; SARS-CoV-2
- Publication
Journal of Cardiac Surgery, 2020, Vol 35, Issue 6, p1388
- ISSN
0886-0440
- Publication type
letter
- DOI
10.1111/jocs.14649